SELLAS Life Sciences Group (NASDAQ:SLS) Announces Earnings Results, Beats Expectations By $0.02 EPS
SELLAS Life Sciences Group (NASDAQ:SLS) reported its earnings results, beating analysts' expectations by $0.02 EPS. The company posted a ($0.06) EPS for the quarter, surpassing the consensus estimate of ($0.08). Despite this, the stock fell 1.3% to $1.49. Analysts have mixed ratings, with one Buy and one Sell rating. Institutional investors have made significant changes to their positions in the stock. SELLAS focuses on developing cancer immunotherapies, with its lead product in Phase 3 trials for acute myeloid leukemia.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02, FiscalAI reports.
SELLAS Life Sciences Group Stock Down 1.3%
SLS stock traded down $0.02 during trading on Wednesday, hitting $1.49. 3,839,963 shares of the company's stock traded hands, compared to its average volume of 2,785,050. SELLAS Life Sciences Group has a 52 week low of $0.77 and a 52 week high of $2.48. The stock has a fifty day moving average price of $1.82 and a two-hundred day moving average price of $1.77. The stock has a market capitalization of $186.37 million, a price-to-earnings ratio of -4.66 and a beta of 2.64.
Analyst Ratings Changes
SLS has been the subject of several analyst reports. Maxim Group upped their target price on SELLAS Life Sciences Group from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SELLAS Life Sciences Group presently has an average rating of "Hold" and a consensus target price of $7.00.
Check Out Our Latest Analysis on SELLAS Life Sciences Group
Institutional Trading of SELLAS Life Sciences Group
Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP increased its holdings in shares of SELLAS Life Sciences Group by 23,550.0% in the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company's stock worth $5,947,000 after acquiring an additional 2,704,007 shares during the period. Geode Capital Management LLC boosted its position in SELLAS Life Sciences Group by 168.2% during the 2nd quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company's stock worth $4,819,000 after acquiring an additional 1,379,988 shares during the period. Vanguard Group Inc. raised its stake in shares of SELLAS Life Sciences Group by 2.8% during the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company's stock valued at $11,012,000 after purchasing an additional 185,106 shares in the last quarter. Rhumbline Advisers bought a new position in SELLAS Life Sciences Group in the 2nd quarter valued at about $297,000. Finally, XTX Topco Ltd acquired a new position in SELLAS Life Sciences Group during the 2nd quarter valued at about $168,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.
About SELLAS Life Sciences Group
(Get Free Report)SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
- Five stocks we like better than SELLAS Life Sciences Group
- Insider Buying Explained: What Investors Need to Know
- Rare Earth Stocks: The Truce That Isn't a Truce
- Do ETFs Pay Dividends? What You Need to Know
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- How to Use Stock Screeners to Find Stocks
- C3.ai's Reset: Why New Leadership Could Spark a Turnaround
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
